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right side shows the train-of-four count predicted
effect.

Abstract

The drug display shows the administration and
effects of three different drugs: measuring sedation,
pain, and muscle relaxation. The y-axes of the graphs
show the drug concentration, and the x-axes are time.
The vertical lines show a bolus of the drug, and then
the solid line is the predicted drug effect site
concentration (from the model). The dotted lines show
what the drug levels will be in the near future, allowing
time for the anesthesiologist to better think ahead and
adjust medications if necessary. On the far right of the
display, the predicted clinical effect is shown.

Neuromuscular blocking agents are used in the
operating room to allow safe intubation and prevent
dangerous movement during surgery. Six patients
scheduled for laparoscopic surgery were monitored
throughout the operation. We then adjusted the
pharmacodynamic model parameters to better fit
individual patient responses. Adjusting the models as
the patient began to recover provided significantly
better prediction of recovery from rocuronium when
adjusted at a train-of-four ratio of 0.3. When these
predictions are displayed to an anesthesiologist, or an
astronaut who may be less trained in anesthesia, they
may help in determining if another bolus of
rocuronium or a reversal agent should be
administered, or when to expect spontaneous muscle
activity for safe extubation.

During surgery anesthesia may be used for sedation
(rendering the patient unconscious and unaware of their
surroundings), analgesia (pain), or for neuromuscular
(NMB) blockade (muscle relaxation). The drug display
shows this information in real time and will eventually
adapt the model to specific during the surgery to reflect
each patient’s needs and sensitivity to the medication.
The plot on the left shows the drug concentrations
predicted in the subject’s body, while the plot on the
right shows the predicted effect of the patient to the
drug given. In the case of muscle relaxants, a
commonly used measure of effect called Train-of-four
(TOF) count is displayed.

1. Introduction
Neuromuscular blocking agents are widely
administered to patients during operations. On the
space station, anesthesia may be used as emergency
tratment for an astronaut, or animals may be put to
sleep for biology experiments such as dissections or
small implant surgeries. Astronauts come from all
disciplines and are rarely trained in anesthesiology. An
anesthesia display such as the one developed in our lab
(Figure 1) could be extremely useful in such a
situation1. Either the drugs given could be
automatically tracked or the astronauts could enter the
information by hand, stating what drug was given at
what time. The anesthesia drug display could then
calculate in real time what the predicted effects of the
drug are on the animal or astronaut.

The purpose of relaxing a patient is to avoid
unwanted muscular responses. One example of this is
for intubation2. As the anesthesiologist places a tube
down the patient’s trachea and connects it to a
ventilator, the patient may have a gag reflex. Another
possible reaction would be contractions in the abdomen
due to a surgical stimulus2. The doctor does not want
the abdomen to contract while he has sensitive surgical
instruments (i.e. a knife) in the area. Muscle relaxants
(neuromuscular blocking agents) suppress reactions
like this allowing for easier care and management by
healthcare professionals3.
Monitoring of neuromuscular blockade and its
effects is most often accomplished with train of four
stimulation and measurement. TOF measurement
consists of four short current stimulations, which cause

Figure 1. Anesthesia Drug Display Prototype. The
neuromuscular blockade portion is shown. The left
section shows the effect site drug concentration and the
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the adductor pollicis (thumb and index finger) to twitch
four times4. As the muscle relaxant takes effect, the
patient response reduces to three twitches, then two,
one, and finally zero. At zero twitches the
neuromuscular blockade is in full effect and the patient
is very relaxed, so that muscles should not respond to a
given stimuli. At four twitch responses the TOF ratio is
used. This is a measure of the strength of the fourth
twitch response (T4) divided by the strength of the first
twitch response (T1). Using this measure allows more
fidelity in determining how close to normal a person is
with respect to neuromuscular function. A ratio of 1
means that neuromuscular function is normal and that
four full twitch responses are present. The lower the
ratio, the more relaxed a person is and the weaker their
response to a given stimulus.

patient’s thumb and index finger and taped in place
(tape was applied between the thumb and index finger
to prevent sensor movement during surgery, see Figure
2). The sensor was placed on the most convenient arm.
Preference was given to the arm without the IV (the
sensor was placed on the right arm in most cases). The
arm was then wiped with an alcohol pad to remove oil
from the skin and allow better electrode performance.
A Smiths STS-400 disposable skin temperature sensor
was placed on the palm and connected to the Datex
monitor. As soon as the patient lost consciousness, the
electrodes were placed on the wrist, above the ulnar
nerve. Time permitting, small stimulations from the
Microstim Plus were used to help locate the ulnar nerve
at the arm and determine the optimal position for
electrode placement.

The models used to predict patient reactions to the
drug can be split into two categories: pharmacokinetic
and pharmacodynamic5. Pharmacokinetic models are
those that predict the concentration of the drug in the
bloodstream, and the pharmacodynamic models take
this drug concentration and predict the effect on the
patient.

The Datex monitor automatically set the
supramaximal current by delivering single twitch
stimulations starting at 40 mA, and then increasing
current levels in 5 mA increments until the twitch
response reached a maximum strength. Then the
current was automatically increased 20% for
supramaximal current. This maximum twitch response
was the baseline value for T1 strength. In the cases that
a maximum response was not found, the stimulator
current was set to deliver 70 mA, and the twitch
response was automatically set as the baseline T1
strength. Train-of-four response was measured every
20 seconds using a stimulation pulse duration of 100
µsec. We recorded the times when recovery of 0.7 TOF
ratio was reached. The sensor and electrodes were
removed before the patient regained consciousness.

The pharmacokinetic (PK) model used in this study
is the Wierda three-compartment model. The three
compartments consist of the bloodstream, muscular
tissues, and fatty tissues. An additional, negligable
compartment represents the effect site in the body. The
model includes parameters that account for
equilibration between these compartments. The drug
display implimentation of the model is the same
implementation as Stanpump, a well-known anesthesia
modeling simulation6. The pharmacodynamic (PD)
model used this study is Plaud’s model4. This model
uses the Hill equation to calculate the TOF ratio
response (from the effect site drug concentration, at the
hand)4.

2. Methods
2.1 Experimental Setup
At the beginning of each case the NMT module was
plugged into the Datex AS/3 monitor. A Toshiba
Satellite Pro Pentium III laptop running Windows XP
was connected to each device. The Datex monitor was
connected directly through the serial port. Rugloop was
used to collect all information from the Datex monitor.
Drug boluses were given through the intravenous (IV)
line.

Figure 2. Train of four stimulator and sensor.

2.2 Data Analysis
Patient details are summarized in Table 1. Patient
data was excluded from analysis due to the following
criteria: the NMB agent succinylcholine was
administered, data was visually noisy, or if TOF ratio
did not recover to 0.7 before reversal. One patient was

During preparation for surgery in the operating
room, the Datex Mechanosensor was placed on the
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with circles show which points were used to calculate a
new γ value.

excluded due to a communication problem with the
computer and the equipment. A total of 6 patients (out
of 20 total) met the inclusion criteria for TOF ratio
analysis.
Subject

Age

#

(years)

(kg)

(cm)

1

29

67.6

172

Male

2

28

76.8

183

Male

3

41

104.1

180

Male

4

60

60

160

Female

5

22

72.1

172

Male

6

34

53.5

165

Female

Mean

36

72

172

4M/2F

2.2.1 Post Hoc determination of best-fit EC50 &
γ using Nonlinear Least Squares

Weight Height Gender
A nonlinear least squares method was performed in
MATLAB to find the best-fit pharmacodynamic
parameters, EC50 and γ, which predict the effect (T1
strength or TOF ratio) using the Hill equation,
Equation 2. (Ceff was calculated using the Wierda PK
model.) Effect was the TOF ratio, E0 was the effect
with no drug present (TOF ratio = 1), and Emax was the
mazimum effect possible (TOF = 0).
γ
C eff
(2)
Effect = E 0 + (E max −E 0 ) γ
γ
EC50 + C eff

14
18
9
St. Dev.
Table 1. Subject details: age, weight, height, and gender
of the subjects who met the inclusion criteria for TOF ratio 2.2.2 Calculation of patient specific EC & γ
50
analysis.

When TOF ratio recovered to 0.2, a new EC50 was
calculated using Equation 3, and Ceff from the Wierda
PK model. The EC50 was calculated and averaged over
three data points (the first minute above the recovery
threshold). This averaging method was used to reduce
the variability, as well as to reduce the influence of
possible spikes in the data when calculating the new
EC50 value, hopefully resulting in a more accurate
prediction.

The data analysis focused on the recovery phase
only of each patient’s neuromuscular function. Figure 3
shows an example of how the data was clipped for this
analysis. In order to focus on the recovery phase, the
data set was clipped after the onset, or maximum
effect, occurred. Data was also clipped before
administration of reversal agent so that recovery results
of only rocuronium were studied. In the cases where
maintenance doses of rocuronium were delivered, the
data was clipped before the maintenance dose was
administered.

 (−TOFratio ) 
EC 50 = C eff 

 (TOFratio − 1) 

1/ γ

(3)

Adjustment of γ was also explored. The new γ was
calculated using a rearranged Hill equation, Equation 4.
γ was calculated using the newly adjusted EC50 value at
each point between recovery of 0.2-0.3 TOF ratio. The
gammas calculated were averaged to find a new,
patient specific γ.

 (−TOFratio ) 

Ln
(TOFratio − 1) 

γ =
(4)
 EC50 

Ln
 C eff 



Figure 3. The shaded regions of the figure show where
the data was clipped. (Notice the sharp rise in response
due to neostigmine administration near the end of the
data set.) The unshaded region is the recovery portion
of the data used for analysis. The dashed line
represents the model predicted response. . The points
highlighted as dots are the three points used to
calculate a new EC50 value. The points highlighted
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3. Results

Time to TOF Ratio Recovery of 0.7 (in minutes)
(using average population EC50 and γ)

3.1 Nonlinear Least Squares determination
of best-fit PD Parameters, EC50 & γ
Table 2 shows the γ and EC50 parameter values for
each subject, which provided the best fit to TOF ratio
data when the Wierda PK model was used to calculate
Ceff.

Post hoc
Nonlinear Least Squares
Calculations of γ and EC50
Subject

EC50

γ

1

510

3.9

2

935

10.7

3

565

6.1

4

459

4.4

5

603

5.2

6

790

5.5

Average

644

6.0

Measured Predicted
Time
Time
Difference

Subject EC50 γ
1

644

6

58.9

52.6

-6.3

2

644

6

29.8

42.5

12.6

3

644

6

64.3

56.3

-8.0

4

644

6

59.5

45.5

-14.0

5

644

6

53.3

50.3

-3.0

6

644

6

55.3

61.3

6.0

Average

8.3

Std. Dev.
4.2
Table 3. The time to recovery of 0.7 TOF ratio, in
minutes, using the average population γ and EC50. The
difference between the measured and predicted times
are also shown.
Time to TOF Ratio Recovery of 0.7 (in minutes)
(with EC50 calculations)

Std. Dev.
182
2.4
Table 2. Gamma and EC50 values which provide the
best fit to TOF ratio data in each subject.

Subject

3.2 Adjustment of PD Parameters
Tables 3-6 show TOF times to 0.7 recovery,
measured and predicted (before and after model
adjustments). The resulting time differences in
estimating extubation (TOF = 0.7) are also shown.
Table 3 shows these recovery times using the
unadjusted, average population values for γ and EC50.
The EC50 value was adjusted at recovery ratio of 0.2 in
Table 4. Table 5 shows the results when γ was also
adjusted, at a recovery ratio of 0.2-0.3. At TOF ratio
recovery of 0.3, the EC50 was adjusted again and the
results are shown in Table 6. Adjusting the EC50 value
at 0.3 recovery results in a closer prediction of
extubation time than the EC50 adjustment at 0.2
recovery (2.5 rather than 3.5 minutes).

Adjusted
EC50
γ

Measured Predicted
Time
Time Difference

1

530

6

58.9

59.6

0.7

2

875

6

29.8

32.9

3.0

3

565

6

64.3

61.3

-3.0

4

491

6

59.5

54.8

-4.7

5

745

6

53.3

45.6

-7.7

6

791

6

55.3

53.6

-1.7

Average

3.5

Std. Dev.
2.5
Table 4. The time to recovery of 0.7 TOF ratio, in
minutes, using the average population γ and EC50
adjusted at recovery of 0.2 TOF ratio. The difference
between the measured and predicted times are also
shown.
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that the models produce will be accurate within an
average of 3.5 minutes using TOF ratio. This is about a
50% average improvement over using the population’s
average pharmacodynamic parameters to predict
recovery time. Without adjustments, the predictions
would be within about 8.3 minutes. This patientspecific prediction of recovery time may help the
anesthesiologist better manage care of each patient,
such as in determining when is necessary and effective
to administer reversal and maintenance doses. The
clinical significance of this is that the anesthesiologist
can look into the future and have a quantitative
prediction of the time left before a patient is expected
to recover. It is also useful for situations where
someone such as an astronaut less familiar with
anesthesia may be required to administer drugs to a
fellow astronaut or for animal experiments. This
analysis leads to conclusion that an effective way to
adjust the neuromuscular PD models reliably is to
measure the TOF ratio during recovery (at 0.2) and use
that information as feedback into the model by
adjusting the parameters real-time.

Time to TOF Ratio Recovery of 0.7 (in minutes)
(with EC50 and γ calculations)
Subject

Adjusted Adjusted Meas. Pred.
EC50
Time Time Difference
γ

1

530

5.7

58.9 59.9

1.0

2

875

6.5

29.8 32.5

2.7

3

565

5.8

64.3 61.3

-3.0

4

491

4.8

59.5 56.2

-3.3

5

745

7.0

53.3 44.6

-8.7

6

791

5.7

55.3 53.6

-1.7

Average
3.4
Std.
Dev.
2.7
Table 5. The time to recovery of 0.7 TOF ratio, in
minutes, using γ calculated from 0.2-0.3 TOF ratio
recovery, and EC50 adjusted at recovery of 0.2 TOF
ratio. The difference between the measured and
predicted times are also shown.

The EC50 values have a fairly large variance
(standard deviation of 162), which is consistent with
other studies performed using rocuronium (Plaud’s
standard deviation of 157). The variability of these
EC50s were comparable to the variability in Plaud’s
dataset, suggesting that the optimized EC50 values
derived in this study are accurate. Variation for γ
(standard deviation of 3.8) in this study is fairly high.
An explanation for this variability is that there are a
small number of patients.

Time to TOF Ratio Recovery of 0.7 (in minutes)
(with EC50 and γ calculations)
Subject

Adjusted Adjusted Meas. Pred.
EC50
Time Time Difference
γ

1

546

5.7

58.9 57.6

-1.3

2

910

6.5

29.8 31.3

1.5

3

573

5.8

64.3 60.3

-4.0

4

466

4.8

59.5 57.5

-2.0

5

602

7.0

53.3 55.6

2.3

6

825

5.7

55.3 50.9

-4.3

5. Limitations
One major limitation in this study was that it was an
observational study. The primary effect was that there
was only a small window of time in which to calibrate
the stimulator and sensor, and reversal agent was often
given before TOF rato recovery reached 0.7. The
results of this study also may be limited to the patient
population studied and the Datex mechanosensor used
to collect the data. There were some problems with the
sensor, in that the baseline calibration shifted during
surgery in several cases so that the final T1 strength
was up to four times above or below the original
calibrated baseline value of 100%. In addition, reversal
agent was administered in most cases. It is
recommended that future studies allow the patient to
recover without reversal agent for a more complete
dataset.

Average
2.6
Std.
Dev.
1.3
Table 6. The time to recovery of 0.7 TOF ratio, in
minutes, using γ calculated from 0.2-0.3 TOF ratio
recovery, and EC50 adjusted at recovery of 0.3 TOF
ratio. The difference between the measured and
predicted times are also shown.

4. Discussion
Adjusting the EC50 and γ pharmacodynamic
parameters at patient recovery of 0.2 and 0.3 resulted in
more accurate predictions of recovery time using TOF
ratio. Our results indicate that the prediction of time
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6. Future Work

8. References

A future study is needed to explore the relationship
between the T1 strength, TOF count, and TOF ratio.
Adjusting the TOF count in real time could also be
helpful to the anesthesiologists because they are more
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